ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,658Medicare Part D Prescriptions Filled, Including Refills

Rank: 219 out of 1206

$582K Total Retail Price of All Prescriptions

Rank: 99 out of 1206

388 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
59% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Iowa
Lower avg

Schedule Two
Controlled Substances

17% of this provider’s 388 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

17% of this provider’s 388 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 7,010 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $46 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Iowa
HYDROCODONE-ACETAMINOPHEN 554 385 S3 1 7
OMEPRAZOLE 341 240 2 3
SIMVASTATIN 276 207 3 1
LEVOTHYROXINE SODIUM 246 206 4 2
WARFARIN SODIUM 242 199 5 8
AMLODIPINE BESYLATE 235 208 6 6
LISINOPRIL 231 177 7 4
FENTANYL 210 180 S2 8 51
FUROSEMIDE 201 178 9 5
QUETIAPINE FUMARATE 170 118 10 79
TRAMADOL HCL 163 139 11 17
TAMSULOSIN HCL 160 112 12 26
ZOLPIDEM TARTRATE 141 123 13 25
ATORVASTATIN CALCIUM 130 85 14 13
ADVAIR DISKUS 107 47 15 55
DONEPEZIL HCL 104 95 16 29
GABAPENTIN 100 45 17 18
MORPHINE SULFATE ER 99 69 S2 18 114
SPIRIVA 99 47 18 66
BISOPROLOL-HYDROCHLOROTHIAZIDE 98 94 20 108
RAMIPRIL 96 68 21 96
MELOXICAM 95 13 22 35
CARBIDOPA-LEVODOPA 93 85 23 70
CYMBALTA 93 78 23 63
CITALOPRAM HBR 90 47 25 16
LOSARTAN POTASSIUM 81 63 26 20
SERTRALINE HCL 81 57 26 22
POTASSIUM CHLORIDE 79 79 28 12
PREDNISONE 74 60 29 28
CYCLOBENZAPRINE HCL 73 34 R 30 80
SPIRONOLACTONE 73 54 30 41
NADOLOL 70 51 32 267
MIRTAZAPINE 70 58 32 50
TRIAMCINOLONE ACETONIDE 69 42 34 102
ENABLEX 69 20 34 248
METFORMIN HCL 65 36 36 10
PROAIR HFA 65 43 36 49
SINGULAIR 64 18 38 120
BUPROPION XL 64 29 38 151
TRAZODONE HCL 63 37 40 37
BISOPROLOL FUMARATE 62 62 41 202
PANTOPRAZOLE SODIUM 62 14 41 54
NAMENDA 61 51 43 36
AMLODIPINE BESYLATE-BENAZEPRIL 60 58 44 76
FENOFIBRATE 58 54 45 56
FINASTERIDE 56 55 46 90
CRESTOR 56 34 46 30
HALOPERIDOL 55 43 48 187
FAMOTIDINE 51 51 49 65
ATENOLOL 50 45 50 14
FLUTICASONE PROPIONATE 50 30 50 42
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 12, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.